PO.CH01.05 · 化学

天然化合物的活性谱分析鉴定出在亲本和耐药淋巴瘤模型中均具活性的强效化学型

Activity profiling of natural compounds identifies potent chemotypes active in parental and drug-resistant lymphoma models

海报缩略图:天然化合物的活性谱分析鉴定出在亲本和耐药淋巴瘤模型中均具活性的强效化学型
编号 3662 展板 21 时间 4/20 02:00–05:00 区域 Section 38 主讲 Filippo Spriano, PhD
分会场 Natural Products
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Filippo Spriano1, Francesca Ghirga2, Deborah Quaglio2, Mattia Mori3, Alberto J. Arribas1, Bruno Botta2, Francesco Bertoni1

1Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland,2Department of Chemistry and Technology of Drugs, Sapienza University of Rome, Rome, Italy,3Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

摘要 Abstract

中文摘要
背景。尽管多年来取得了巨大进步,仍有太多罹患淋巴瘤的患者死于该病。植物是结构多样的次生代谢产物极为丰富的来源,可提供新型活性化合物。因此,我们在边缘区淋巴瘤(MZL)来源的细胞系(包括对靶向药物获得性耐药者)中筛选了一个经过精选的、由37种天然(主要为植物来源)和天然衍生化合物组成的库。该库由通过化学信息学方法根据其多样性所筛选的分子组成,涵盖16个化学类别,包括蒽醌类、黄酮类、查耳酮类、三萜类、生物碱类、苯乙酮类、二苯甲酮类、香豆素类以及一种二苯并呋喃衍生物。 方法。在6个MZL淋巴瘤来源模型(VL51及3个BTK/PI3K/BCL2抑制剂(i)耐药株;Karpas1718及BTKi/PI3Ki耐药株)中筛选该库的抗增殖活性。细胞以每种化合物0.4 μM、4 μM和40 μM的浓度处理72小时。采用MTT法评估细胞活力,并以DMSO对照进行标准化。数据按类别及各单一化合物在不同剂量和细胞系亚组间进行分析,以增殖降低≥30%作为活性阈值。 结果。在0.4 μM时,大多数化合物仅显示极小的抑制作用,仅vismione B(蒽醌类)表现出部分活性。在4 μM时,在选定的查耳酮类和松萝酸(二苯并呋喃)中观察到中等程度的降低。在40 μM时,出现了明显的类别和化合物依赖性效应。活性最强的化合物——osajin(黄酮类)、熊果酸(三萜类)、松萝酸(二苯并呋喃)、cordoin和4,4′-O-甲氧基查耳酮,在所有模型中均将活力降至<25%。这些化合物还在剂量依赖性研究中得到验证。按类别而言,查耳酮类、黄酮类和蒽醌类是活性最强的化学类别。亲本株与耐药亚株之间的比较显示,大多数活性化合物在两种情形下均保持其活性,表明其作用机制不依赖于耐药性。部分受试黄酮类化合物在VL51中表现出优于Karpas1718的活性。最后,选定的化合物针对CB-33类淋巴母细胞系进行了测试,尤其关注松萝酸(苯并呋喃),其在淋巴瘤细胞中表现出比非淋巴瘤细胞系更强的细胞毒性。 结论。这项对结构多样的天然化合物的筛选将查耳酮类、黄酮类和蒽醌类鉴定为淋巴瘤模型中活性最强的类别。osajin、熊果酸、松萝酸、cordoin和4,4′-O-甲氧基查耳酮在所有模型中可重复的剂量依赖性活性,凸显它们作为有前景的先导骨架,可供进一步机制研究和药物化学优化,以开发新型抗淋巴瘤药物。
查看英文原文 English abstract
Background. Despite the big improvements achieved during the years, too many patients affected by lymphomas still succumb to their disease. Plants represent an extremely rich source of structurally diverse secondary metabolites, which can provide novel active compounds. Thus, we screened a curated library of 37 natural (mostly plant-derived) and nature-derived compounds in cell lines derived from marginal zone lymphoma (MZL), including those with acquired resistance to targeted agents. The library consisted of molecules selected through a cheminformatics approach for their diversity, and spanned 16 chemical classes, including anthranoids, flavonoids, chalcones, triterpenes, alkaloids, acetophenones, benzophenones, coumarins, and a dibenzofuran derivative. Methods. The library was screened for anti-proliferative activity in 6 MZL lymphoma-derived models (VL51, and 3 BTK/PI3K/BCL2 inhibitors (i) resistant; Karpas1718, and BTKi/PI3Ki resistant). Cells were treated with each compound at 0.4 µM, 4 µM, and 40 µM for 72 hours. Cell viability was assessed using an MTT assay, normalized to DMSO controls. Data were analyzed by class and by individual compound across doses and cell-line subgroups, using a ≥30% reduction in proliferation as the threshold for activity. Results. At 0.4 µM, most compounds displayed minimal inhibition, with only vismione B (anthranoid) showing partial activity. At 4 µM, modest reductions were observed in selected chalcones and in usnic acid (dibenzofuran). At 40 µM, clear class- and compound-dependent effects emerged. The most active compounds, osajin (flavonoid), ursolic acid (triterpene), usnic acid (dibenzofuran), cordoin, and 4,4′-O-methoxy-chalcone, reduced viability to <25% across all models. These compounds were also validated in a dose-dependent study. By class, chalcones, flavonoids and anthranoids were among the most active chemical classes. A comparison between parental and resistant sublines revealed that most active compounds retained their activity in both settings, indicating resistance-independent mechanisms of action. Some of the tested flavonoids showed preferential activity in VL51 rather than Karpas1718. Finally, selected compounds were tested against the CB-33 lymphoblastoid cell line, with a particular focus on usnic acid (benzofuran), which demonstrated more cytotoxicity in lymphoma cells than in the non-lymphoma cell line. Conclusions. This screen of structurally diverse natural compounds identified chalcones, flavonoids, and anthranoids as the most active classes in lymphoma models. The reproducible, dose-dependent activity of osajin, ursolic acid, usnic acid, cordoin, and 4,4′-O-methoxy-chalcone across all models highlights them as promising lead scaffolds for further mechanistic studies and medicinal chemistry optimization toward novel anti-lymphoma agents.
利益披露 Disclosure
F. Spriano, None.. F. Ghirga, None.. D. Quaglio, None.. M. Mori, None.. A. J. Arribas, None.. B. Botta, None.. F. Bertoni, None.

← 返回 AACR 2026 检索